单位:[1]Experimental Center, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China医技科室北京市临床医学研究所实验中心首都医科大学附属北京友谊医院[2]National Clinical Research Center for Digestive Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China首都医科大学附属北京友谊医院[3]State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People’s Republic of China[4]Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China医技科室病理科病理科首都医科大学附属北京友谊医院[5]Clinical Laboratory Center, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China医技科室检验科检验科首都医科大学附属北京友谊医院[6]Liver Research Center, National Clinical Research Center for Digestive Diseases, Beijing, People’s Republic of China临床科室国家中心肝病分中心首都医科大学附属北京友谊医院
Liver fibrosis, a major cause of morbidity and mortality worldwide, leads to liver damage, seriously threatening human health. In our previous study, we demonstrated that 14 kDa phosphohistidine phosphatase (PHP14) was upregulated in fibrotic liver tissue and involved in the migration and lamellipodia formation of hepatic stellate cells (HSCs). In this study, we evaluated PHP14 as a therapeutic target for liver fibrosis and investigated the mechanism by which it mediates liver fibrosis. AAV-shPhptl administration significantly attenuates CCl4 -induced liver fibrosis in mice. In particular, fibrosis-associated inflammatory infiltration was significantly suppressed after PHP14 knockdown. Mechanistically, PHP14 regulated macrophage recruitment, infiltration, and migration by affecting podosome formation of macrophages. Inhibition of PHP14 decreased the expression of the fibrogenic signature at the early stage of liver fibrogenesis and the activation of HSCs in vivo. Thus, PHP14 can be considered a potential therapeutic target for liver fibrosis. NEW & NOTEWORTHY PHP14 inhibition via adeno-associated virus (AAV)-mediated gene silencing could potently attenuate carbon tetrachloride (CCl4)-induced liver fibrosis. PHP14 could regulate the migration of macrophages to the site of injury in vivo. PHP14 knockdown in vivo influenced the environment of fibrogenesis and relevant signaling pathways, subsequently affecting myofibroblast activation.
基金:
Beijing Natural Science FoundationBeijing Natural Science Foundation [7202034]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81670539, 81970524, 81773800]
第一作者单位:[1]Experimental Center, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China[2]National Clinical Research Center for Digestive Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China
通讯作者:
通讯机构:[1]Experimental Center, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China[2]National Clinical Research Center for Digestive Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, People’s Republic of China[6]Liver Research Center, National Clinical Research Center for Digestive Diseases, Beijing, People’s Republic of China
推荐引用方式(GB/T 7714):
Anjian Xu,Jichao Zhou,Yanmeng Li,et al.14-kDa phosphohistidine phosphatase is a potential therapeutic target for liver fibrosis[J].AMERICAN JOURNAL of PHYSIOLOGY-GASTROINTESTINAL and LIVER PHYSIOLOGY.2021,320(3):G351-G365.doi:10.1152/ajpgi.00334.2020.
APA:
Anjian Xu,Jichao Zhou,Yanmeng Li,Luyao Qiao,Caicai Jin...&Jian Huang.(2021).14-kDa phosphohistidine phosphatase is a potential therapeutic target for liver fibrosis.AMERICAN JOURNAL of PHYSIOLOGY-GASTROINTESTINAL and LIVER PHYSIOLOGY,320,(3)
MLA:
Anjian Xu,et al."14-kDa phosphohistidine phosphatase is a potential therapeutic target for liver fibrosis".AMERICAN JOURNAL of PHYSIOLOGY-GASTROINTESTINAL and LIVER PHYSIOLOGY 320..3(2021):G351-G365